Literature DB >> 32779603

[Coronavirus disease 2019 (COVID-19) and headaches].

Keisuke Suzuki1.   

Abstract

Over the course of the new coronavirus infectious disease (coronavirus disease 2019; COVID-19) pandemic, our social situation has been changing dramatically, in addition to the substantial efforts made for the early and appropriate management of COVID-19 and preventing this infection spreading. Recently, neurological symptoms associated with COVID-19 have been shown to be not uncommon, with headaches receiving attention as one of the main neurological symptoms. The frequency of headaches associated with COVID-19 ranged from 5.6% to 70.3%, based on 21 clinical studies and 8 meta-analyses. However, headaches were observed in 11.1% to 81.0% of non-COVID-19 individuals, including healthcare workers caring for COVID-19 patients. Although detailed descriptions of headaches were rarely provided in the literature obtained, in this article, I wil discuss the frequency and characteristics of headaches, and the pathophysiology of headaches as it relateds to COVID-19.

Entities:  

Keywords:  COVID-19; headache; neurological complications

Mesh:

Year:  2020        PMID: 32779603     DOI: 10.5692/clinicalneurol.cn-001490

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  1 in total

1.  Characterization of Headache in COVID-19: a Retrospective Multicenter Study.

Authors:  Rafael César Dos Anjos de Paula; Thaís de Maria Frota Vasconcelos; Francisco Bruno Santana da Costa; Lara Albuquerque de Brito; Danielle Mesquita Torres; Alissa Elen Formiga Moura; Danilo Nunes Oliveira; Guilherme Alves de Lima Henn; Pedro Gustavo Barros Rodrigues; Isabelle de Sousa Pereira; Ianna Lacerda Sampaio Braga; Felipe Araújo Rocha; Norberto Anízio Ferreira Frota; Fernanda Martins Maia Carvalho; Milena Sales Pitombeira; José Wagner Leonel Tavares-Junior; Raquel Carvalho Montenegro; Pedro Braga-Neto; Paulo Ribeiro Nóbrega; Manoel Alves Sobreira-Neto
Journal:  Mol Neurobiol       Date:  2021-05-25       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.